Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H29N3O8 |
Molecular Weight | 499.5131 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)[C@@H]([C@H]1CCCCN1C(=O)OC[N+]2=CC(=CC=C2)C(=O)N[C@@H](CO)C([O-])=O)C3=CC=CC=C3
InChI
InChIKey=UBZPNQRBUOBBLN-PWRODBHTSA-N
InChI=1S/C25H29N3O8/c1-35-24(33)21(17-8-3-2-4-9-17)20-11-5-6-13-28(20)25(34)36-16-27-12-7-10-18(14-27)22(30)26-19(15-29)23(31)32/h2-4,7-10,12,14,19-21,29H,5-6,11,13,15-16H2,1H3,(H-,26,30,31,32)/t19-,20+,21+/m0/s1
Molecular Formula | C25H29N3O8 |
Molecular Weight | 499.5131 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Dexmethylphenidate is the dextrorotary form of methylphenidate. Dexmethylphenidate is marketed under the trade name Focalin. Focalin (dexmethylphenidate hydrochloride) is the d-threo-enantiomer of racemic
methylphenidate hydrochloride, which is a 50/50 mixture of the d-threo and l-threoenantiomers. Focalin is a central nervous system (CNS) stimulant, available in three tablet strengths. Each tablet contains dexmethylphenidate hydrochloride 2.5, 5, or 10 mg for oral administration. Dexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment. Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Methylphenidate is a catecholamine reuptake inhibitor that indirectly increases catecholaminergic neurotransmission by inhibiting the dopamine transporter (DAT) and norepinephrine transporter (NET), which are responsible for clearing catecholamines from the synapse, particularly in the striatum and meso-limbic system.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
161.0 nM [Ki] | |||
206.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FOCALIN Approved UseFocalin XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. The effectiveness of Focalin XR in the treatment of ADHD in patients aged 6 years and older was established in two placebo-controlled studies in patients meeting DSM-IV criteria for ADHD. Launch Date2001 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
22.13 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14747426 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
23.72 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14747426 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28590363 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
131.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14747426 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
120.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14747426 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
79.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28590363 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.81 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14747426 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2.68 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14747426 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28590363 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXMETHYLPHENIDATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Other AEs: Vomiting, Agitation... Other AEs: Vomiting Sources: Agitation Tremor Hyperreflexia Muscle twitching Convulsions Euphoria Confusion Hallucinations Delirium Sweating Flushing Headache Hyperpyrexia Tachycardia Palpitations Cardiac arrhythmias Hypertension Mydriasis Mucosal dryness Rhabdomyolysis |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Twitching, Anorexia... AEs leading to discontinuation/dose reduction: Twitching (1%) Sources: Anorexia (1%) Insomnia (1%) Tachycardia (1%) Insomnia (1.8%) |
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Cardiac disorders, Stroke... Other AEs: Increased blood pressure, Heart rate increased... AEs leading to discontinuation/dose reduction: Cardiac disorders (grade 3-5) Other AEs:Stroke (grade 3-5) Myocardial infarction (grade 3-5) Seizures Raynaud's phenomenon Increased blood pressure Sources: Heart rate increased Psychotic symptom (grade 3-5) Psychotic symptom Manic symptom Aggression Growth suppression Priapism Erection prolonged Vascular disorders Visual disturbance |
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Feeling jittery, Anorexia... AEs leading to discontinuation/dose reduction: Feeling jittery (1.8%) Sources: Anorexia (1.2%) Anxiety (1.2%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Agitation | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Cardiac arrhythmias | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Confusion | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Convulsions | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Delirium | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Euphoria | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Flushing | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Hallucinations | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Headache | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Hyperpyrexia | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Hyperreflexia | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Hypertension | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Mucosal dryness | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Muscle twitching | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Mydriasis | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Palpitations | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Rhabdomyolysis | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Sweating | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Tachycardia | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Tremor | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Vomiting | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Anorexia | 1% Disc. AE |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Insomnia | 1% Disc. AE |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Tachycardia | 1% Disc. AE |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Twitching | 1% Disc. AE |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Insomnia | 1.8% Disc. AE |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Aggression | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Erection prolonged | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Growth suppression | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Heart rate increased | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Increased blood pressure | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Manic symptom | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Priapism | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Psychotic symptom | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Vascular disorders | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Visual disturbance | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
|
Raynaud's phenomenon | Disc. AE | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Seizures | Disc. AE | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Psychotic symptom | grade 3-5 | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Cardiac disorders | grade 3-5 Disc. AE |
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Myocardial infarction | grade 3-5 Disc. AE |
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Stroke | grade 3-5 Disc. AE |
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Anorexia | 1.2% Disc. AE |
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Anxiety | 1.2% Disc. AE |
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Feeling jittery | 1.8% Disc. AE |
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 11.0 |
no | |||
Page: 11.0 |
no | |||
Page: 11.0 |
no | |||
Page: 11.0 |
no | |||
Page: 11.0 |
no | |||
Page: 11.0 |
no | |||
Page: 11.0 |
no | no (co-administration study) Comment: Clinically, methylphenidate coadministration did not increase plasma concentrations of the CYP2D6 substrate desipramine. Page: 11.0 |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/15082749/ Page: - |
no | |||
Sources: https://www.pharmgkb.org/pmid/16621932 Page: - |
weak | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12215063/ Page: - |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. | 2002 |
|
A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder. | 2004 Nov |
|
Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder. | 2004 Winter |
|
A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. | 2004 Winter |
|
Attention deficit/hyperactivity disorder: pharmacotherapy. | 2005 Jan |
|
Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder. | 2005 Jul |
|
Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core. | 2005 Mar |
|
ADHD in adolescence and adulthood, with a special focus on the dopamine transporter and nicotine. | 2006 |
|
Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder. | 2006 |
|
A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. | 2006 Dec 20 |
|
[Medical treatments of hyperactive child: about the new pharmaceutical forms of methylphenidate marketed in France]. | 2006 Jan |
|
Misuse of "study drugs:" prevalence, consequences, and implications for policy. | 2006 Jun 9 |
|
The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities. | 2007 Aug |
|
Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. | 2007 Dec |
|
Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. | 2007 Jun 15 |
|
Psychopharmacology of ADHD in pediatrics: current advances and issues. | 2009 |
|
Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder. | 2009 Aug |
|
Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer. | 2009 Jun 29 |
|
A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). | 2009 Jun 8 |
|
Dexmethylphenidate for attention deficit hyperactivity disorder. | 2009 Nov |
|
Real-World Data on: Attention Deficit Hyperactivity Disorder Medication Side Effects. | 2010 Apr |
|
Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder. | 2010 Aug |
|
Use of psychostimulants in patients with dementia. | 2010 Oct |
|
European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. | 2010 Sep 3 |
|
Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling. | 2011 Jan 1 |
Patents
Sample Use Guides
Focalin (Dexmethylphenidate) is administered twice daily, at least 4 hours apart. Focalin may be administered with or without food. The recommended starting dose of Focalin for patients who are not currently taking racemic
methylphenidate, or for patients who are on stimulants other than methylphenidate, is 5
mg/day (2.5 mg twice daily).
Dosage may be adjusted in 2.5 to 5 mg increments to a maximum of 20 mg/day (10 mg twice daily). In general, dosage adjustments may proceed at approximately weekly intervals.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21129986
Dexmethylphenidate inhibition [3H]dopamine uptake at human DAT expressed in mouse N2A cells with IC50 156 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 21:08:42 GMT 2025
by
admin
on
Tue Apr 01 21:08:42 GMT 2025
|
Record UNII |
0H8KZ470DW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
1729
Created by
admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
|
||
|
FDA ORPHAN DRUG |
878522
Created by
admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2014450-84-9
Created by
admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
|
ALTERNATIVE | |||
|
300000005913
Created by
admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
|
PRIMARY | |||
|
1996626-29-9
Created by
admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
|
PRIMARY | |||
|
0H8KZ470DW
Created by
admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
|
PRIMARY | |||
|
2562176
Created by
admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
|
PRIMARY | |||
|
10916
Created by
admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
|
PRIMARY | |||
|
134823895
Created by
admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
|
PRIMARY | |||
|
C166420
Created by
admin on Tue Apr 01 21:08:42 GMT 2025 , Edited by admin on Tue Apr 01 21:08:42 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
EXCRETED UNCHANGED |
URINE
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
EXCRETED UNCHANGED |
FECAL
|
||
|
BINDER->LIGAND |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
FASTED STATE PHARMACOKINETIC PHARMACOKINETIC |
|
||
Biological Half-life | PHARMACOKINETIC |
|
IN HEALTHY ADULT SUBJECTS PHARMACOKINETIC |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
after AZSTARYS administration PHARMACOKINETIC |
|
||